Related Experiment Videos
Bone density and metabolism in thalassaemia.
R Lala1, P Chiabotto, M Di Stefano
1Department of Paediatric Endocrinology, Regina Margherita Children's Hospital, Turin, Italy.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|March 26, 1999
Summary
Thalassaemia patients exhibit significant bone issues like osteoporosis and growth failure, which worsen with age. Bone metabolism markers showed no clear changes despite iron chelation therapy.
Area of Science:
- Pediatric Endocrinology
- Hematology
- Bone Metabolism
Background:
- Beta-thalassaemia is a genetic blood disorder requiring regular transfusions.
- Iron overload from transfusions necessitates chelation therapy.
- Bone complications are common in thalassaemia patients.
Purpose of the Study:
- To assess bone alterations in thalassaemia patients undergoing iron chelation.
- To evaluate the impact of desferrioxamine and deferiprone on bone health.
- To investigate bone mineral density and metabolic markers.
Main Methods:
- Studied 27 thalassaemia patients (aged 8.1-14.9 years) with auxological evaluations and dual X-ray absorptiometry.
- Measured bone metabolic markers for osteoclastic and osteoblastic activity.
- Compared outcomes after 1 year of desferrioxamine vs. deferiprone chelation.
Main Results:
- Patients showed widespread bone alterations including osteoporosis, growth failure, and delayed bone age.
- Bone mineral density (Z score) and height SDS inversely correlated with age.
- No significant changes in bone metabolic markers were observed.
Conclusions:
- Thalassaemia is associated with progressive osteoporosis and growth insufficiency.
- Current chelation therapies did not reveal clear alterations in bone metabolism markers.
- Further MR imaging is needed to understand bone marrow hyperplasia's role in osteopathy.